Abstract A056: Targeting the mutant p53 cancer cell secretome sensitizes tumors to gemcitabine/nab-paclitaxel chemotherapy and reduces metastasis in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal and metastatic malignancy, with standard-of-care treatments, such as gemcitabine/nab-paclitaxel (GnP) offering limited improvement for patients with advanced disease. We and others have shown that co-targeting key factors in combination with chemotherapy...